These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2272424)

  • 1. [Anticoagulants and antiaggregants in ischemic heart disease].
    Motolese M
    G Ital Cardiol; 1990 Aug; 20(8):746-57. PubMed ID: 2272424
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute coronary syndromes: new developments in pharmacological treatment strategies.
    Gylys K; Gold M
    Crit Care Nurse; 2000 Apr; Suppl():3-14; quiz 15-6. PubMed ID: 11876169
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current use of anti-hemostatics in ischemic cardiopathy].
    Bolao IG; Alegría E; Iglesias I; Velasco S; Fidalgo ML; Gómez JA; Huelmos A
    Rev Med Univ Navarra; 1990; 34(4):219-26. PubMed ID: 2152748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term use of blockers of the platelet ADP receptor in acute coronary syndromes.
    De Caterina R; Zimarino M
    Haematologica; 2001 Nov; 86(11 Suppl 2):25-7. PubMed ID: 11926769
    [No Abstract]   [Full Text] [Related]  

  • 5. [Unstable angina pectoris: distress signal in coronary heart disease].
    Follath F
    Praxis (Bern 1994); 1995 Feb; 84(6):153-4. PubMed ID: 7871297
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antiplatelets and anticoagulants in acute coronary syndromes: levels of evidence].
    Páramo JA; García R; Rodríguez P; de Gaona ER
    Rev Med Univ Navarra; 2007; 51(1):23-7. PubMed ID: 17555117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of antiplatelet agents in the treatment of ischemic cardiopathy].
    Bonhorst D
    Rev Port Cardiol; 1989 Apr; 8(4):261-4. PubMed ID: 2534356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of the PROTECT-TIMI-30 trial.
    Valgimigli M; Biondi-Zoccai GG; Agostoni P
    J Am Coll Cardiol; 2007 Feb; 49(6):729-30; author reply 730-1. PubMed ID: 17291940
    [No Abstract]   [Full Text] [Related]  

  • 9. Contemporary view of the acute coronary syndromes.
    Moustapha A; Anderson HV
    J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619
    [No Abstract]   [Full Text] [Related]  

  • 10. [Heparin therapy and coronary cardiopathy].
    Branzi A; Melandri G
    Cardiologia; 1996 Dec; 41(12):1147-54. PubMed ID: 9064212
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
    Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy for ischemic heart disease in the elderly.
    Frishman WH; Miller KP
    Geriatrics; 1988 Dec; 43 Suppl():46-56. PubMed ID: 3056785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation in coronary heart disease: heparin and warfarin trials.
    Lopez LM; Mehta JL
    Cardiovasc Clin; 1987; 18(1):215-29. PubMed ID: 2955891
    [No Abstract]   [Full Text] [Related]  

  • 14. Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.
    Kelly RV; Steinhubl S
    Heart; 2005 Jun; 91 Suppl 3(Suppl 3):iii16-9. PubMed ID: 15919646
    [No Abstract]   [Full Text] [Related]  

  • 15. [Blood platelet aggregation inhibitors in the treatment of heart diseases].
    Verheugt FW
    Ned Tijdschr Geneeskd; 1993 Aug; 137(33):1647-50. PubMed ID: 8371794
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aspirin in ischemic heart disease].
    Penkov N; Sirakova V
    Vutr Boles; 1990; 29(4):12-7. PubMed ID: 2281654
    [No Abstract]   [Full Text] [Related]  

  • 18. Warfarin, aspirin, or both after myocardial infarction.
    Amit G; Ilia R; Zahger D
    N Engl J Med; 2003 Jan; 348(3):256-7; author reply 256-7. PubMed ID: 12530435
    [No Abstract]   [Full Text] [Related]  

  • 19. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.
    Antman EM
    Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.